for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc (ADR)

AZN

Latest Trade

55.46USD

Change

-0.46(-0.81%)

Volume

2,585,067

Today's Range

54.72

 - 

55.45

52 Week Range

36.15

 - 

64.94

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
55.91
Open
55.29
Volume
2,585,067
3M AVG Volume
139.32
Today's High
55.45
Today's Low
54.72
52 Week High
64.94
52 Week Low
36.15
Shares Out (MIL)
1,312.27
Market Cap (MIL)
148,883.40
Forward P/E
28.80
Dividend (Yield %)
2.48

Next Event

AstraZeneca PLC at Citi European Healthcare Bus Tour (Virtual)

Latest Developments

More

AstraZeneca Says Lynparza Recommended For EU Nod By CHMP

Merck & Co Inc Says Lynparza Improved Median Progression-Free Survival To Over 4.5 Years Vs 13.8 Months With Placebo

Serum Institute To Resume Trials Of Oxford-AstraZeneca COVID-19 Vaccine - PTI Report In Times Of India

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc (ADR)

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.5K

2018

22.1K

2019

24.4K

2020(E)

26.4K
EPS (USD)

2017

2.140

2018

1.730

2019

1.750

2020(E)

1.960
Price To Earnings (TTM)
69.00
Price To Sales (TTM)
5.79
Price To Book (MRQ)
12.11
Price To Cash Flow (TTM)
25.51
Total Debt To Equity (MRQ)
161.37
LT Debt To Equity (MRQ)
127.60
Return on Investment (TTM)
4.83
Return on Equity (TTM)
3.36

Latest News

Latest News

Latest on the worldwide spread of coronavirus

Latin America has recorded around 8.7 million coronavirus cases and over 322,000 deaths - both figures the highest of any region, according to a Reuters tally. Despite widespread compliance and aggressive lockdown measures in many countries, experts suggest that rampant...

COVID-19 vaccine makers see EU shield against side-effect claims

Vaccine makers will be indemnified in Europe if their COVID-19 shots cause unexpected side-effects, an industry official said on Tuesday, urging European regulators to set up more predictable schemes to compensate possible victims.

FACTBOX-EU tries to catch-up after U.S., UK spend billions to secure coronavirus vaccines

(Adds ReiThera; updates Sanofi, AstraZeneca, Novavax, Johnson & Johnson) Sept 21 (Reuters) - The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines. The European Union also signed its...

FACTBOX- The race for a coronavirus vaccine

(Updates Moderna, adds Beijing Wantai Biological Pharmacy, COVAXX, University Hospital Tuebingen, China's Institute of Biotechnology) Sept 21 (Reuters) - More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human...

EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers

The European Medicines Agency (EMA) has recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said on Monday.

AstraZeneca-Merck's Lynparza wins EU panel recommendation for cancer treatments

A European regulatory panel has recommended the approval of Lynparza, a blockbuster cancer treatment developed by AstraZeneca Plc and Merck & Co Inc, to treat two separate forms of cancer.

AstraZeneca says COVID-19 vaccine trial in U.S still on hold

AstraZeneca Plc <AZN.L> said on Saturday that its COVID-19 vaccine trial in the United States is still on hold.

AstraZeneca says Tagrisso shown to slow lung cancer spreading to brain

AstraZeneca's top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday.

Morocco orders COVID-19 vaccine as cases approach 100,000

Morocco on Friday signed a deal with Russia's R-Pharm to buy a COVID-19 vaccine produced under a licence from Britain’s AstraZeneca, the health ministry said, as its total number of cases approached 100,000.

AstraZeneca's trial illnesses may not be due to COVID-19 shot, Oxford University says

The adverse events that led to a pause in trials evaluating AstraZeneca Plc's COVID-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted online by the Oxford University.

Italy could have AstraZeneca COVID-19 shots by end November, IRBM biotech says

Italy could have its first shots of British drugmaker AstraZeneca's potential COVID-19 vaccine by the end of November, the managing director of IRBM told Reuters.

AstraZeneca's trial illnesses may not be due to COVID-19 shot - Oxford Univ

The adverse events that led to a pause in trials evaluating AstraZeneca Plc's COVID-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted https://covid19vaccinetrial.co.uk/files...

Serum Institute gets approval to resume India trial of AstraZeneca COVID vaccine: source

Serum Institute of India has received Indian regulatory approval to resume local clinical trials of AstraZeneca's potential COVID-19 vaccine, a source familiar with the matter said on Wednesday.

Serum Institute to resume India trial of AstraZeneca's COVID-19 vaccine -report

India's drugs regulator has given approval to Serum Institute of India to resume local clinical trials of the potential COVID-19 vaccine developed by AstraZeneca and Oxford University, the Times of India reported on Wednesday, citing the Press Trust of India.

BRIEF-Serum Institute To Resume Trials Of Oxford-AstraZeneca COVID-19 Vaccine - PTI Report In Times Of India

* SERUM INSTITUTE GETS INDIAN REGULATORY APPROVAL TO RESUME TRIALS OF OXFORD-ASTRAZENECA COVID-19 VACCINE - PTI REPORT IN TIMES OF INDIA Source text: (https://bit.ly/2ZIt058) Further company coverage:

U.S. FDA investigating AstraZeneca's COVID-19 vaccine candidate

The U.S. Food and Drug Administration said on Tuesday AstraZeneca Plc's COVID-19 vaccine trial in the United States is still on hold, and it was working with the company to figure out if there was a significant safety issue or not.

U.S. FDA's Hahn plans 'significant' work with AstraZeneca in COVID-19 trial inquiry

The top U.S. Food and Drug Administration official on Tuesday confirmed AstraZeneca Plc's U.S. COVID-19 vaccine trial is on hold, saying the agency is planning to do "very significant work" with the company as it conducts its investigation after an illness in a participant...

Brazil authorizes additional 5,000 volunteers for AstraZeneca COVID-19 vaccine

Brazil's health regulator Anvisa on Tuesday authorized AstraZeneca PLC to test its COVID-19 vaccine on an additional 5,000 volunteers in the country for clinical Phase III trials, the Sao Paulo university coordinating the test said.

AstraZeneca resumes COVID-19 vaccine trials in South Africa, health department says

AstraZeneca has resumed COVID-19 vaccine trials in South Africa, more than a week after tests were paused due to serious side effects in a participant in Britain, an official at the country's Department of Health told Reuters on Tuesday.

UPDATE 1-Brazil authorizes additional 5,000 volunteers for AstraZeneca COVID-19 vaccine

Brazil's health regulator Anvisa on Tuesday authorized AstraZeneca PLC to test its COVID-19 vaccine on an additional 5,000 volunteers in the country for clinical Phase III trials, the Sao Paulo university coordinating the test said.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up